Eli Lilly disclosed additional safety and tolerability data for retatrutide at the American Diabetes Association meeting and in The Lancet, extending results from TRANSCEND-T2D-1. The company reported that among 403 participants receiving retatrutide, 7 experienced arrhythmias and 3 had major cardiovascular complications, compared with none in the placebo group. The update keeps attention on retatrutide’s near-term risk–benefit profile as obesity drug developers race to define long-term cardiovascular safety and differentiate efficacy in people with and without type 2 diabetes. Lilly has previously highlighted rapid weight loss with the next-generation, multi-receptor approach.